Erectile dysfunction

Erectile dysfunction (ED) is the persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual activity. It concerns erectile function specifically, rather than sexual desire, ejaculation, orgasm, or fertility, although difficulties in these areas may coexist. Its likelihood increases with age, but it is not an inevitable consequence of aging. “Impotence” is an older, less precise term. (niddk.nih.gov)

Erectile function depends on coordinated vascular, nervous, hormonal, and psychological processes. ED can therefore arise from several interacting causes, including diabetes mellitus, vascular disease, neurological injury, medication effects, and psychological factors. It can affect the quality of life of individuals and their partners, and it is recognized as a marker associated with cardiovascular disease, rather than proof that cardiovascular disease is present in every affected person. (niddk.nih.gov)

Clinical assessment combines medical, sexual, and psychosocial history with examination and selected investigations. Established management approaches include psychological interventions, oral medicines, locally administered medicines, vacuum devices, and penile prostheses. Their use depends on the underlying conditions, treatment goals, benefits, risks, and individual preferences. The subject also encompasses population patterns, the history of sexual medicine, barriers to care, and the evidence supporting newer interventions. (niddk.nih.gov)

Definition and clinical boundaries

Erectile dysfunction (ED) is the persistent or recurrent difficulty attaining or maintaining a penile erection with sufficient rigidity for satisfactory sexual activity. The definition includes both an inability to become adequately erect and an inability to sustain an initially adequate erection. Complete absence of erections is not required: repeated difficulty despite some successful erections also falls within its scope. The American Urological Association’s 2018 guideline frames the defining impairment in terms of sufficient penile rigidity for sexual satisfaction, rather than simply the presence or absence of an erection. This makes functional adequacy—not a fixed erection duration—the central clinical boundary. (auanet.org)

An isolated unsuccessful erection does not by itself establish a persistent erectile disorder. Occasional difficulties may occur during temporary stress, tiredness, or excessive alcohol consumption. Conversely, the ability to have an erection on some occasions, including on waking, does not exclude recurrent difficulties during sexual activity. The distinction therefore rests on a continuing or recurring pattern rather than a single episode or the requirement that every attempted erection fail. The broad urological definition specifies consistency or recurrence without assigning a universal numerical threshold for unsuccessful attempts. (nhs.uk)

ED is distinct from reduced sexual desire, or low libido, which concerns interest in sexual activity rather than penile rigidity. A person may retain sexual interest but experience erectile difficulty, while reduced desire can occur without an established erectile impairment; both problems can also coexist. Clinical descriptions therefore distinguish desire from erectile response instead of treating lack of interest as equivalent to inability to become erect. The European Association of Urology similarly separates sexual desire, arousal, erectile function, ejaculation, and orgasm when describing the domains assessed in a sexual history. (nhs.uk)

Ejaculatory disorders concern semen emission or expulsion, including ejaculation that occurs too early, is markedly delayed, or is absent. Orgasmic disorders concern the subjective experience of sexual climax. These are not interchangeable with ED: absent ejaculation can occur with a normal orgasmic sensation, illustrating that even ejaculation and orgasm are separable functions. Infertility, by contrast, concerns reproductive capacity and failure to achieve pregnancy, not the adequacy of an erection. The NICHD describes a commonly used clinical threshold of one year of regular unprotected intercourse without pregnancy. Erectile impairment may interfere with intercourse, but neither that threshold nor sperm function is part of the definition of ED. Coexisting sexual or reproductive problems are consequently described separately rather than subsumed under the erectile diagnosis. (uroweb.org)

The historical term impotence is less precise because it can imply a broad deficiency in male sexual capacity rather than identify the particular function affected. The National Institutes of Health consensus statement issued in December 1992 recommended replacing it with erectile dysfunction. The panel’s report, published in JAMA in 1993, identified both confusing terminology in clinical and basic-science investigations and the pejorative implications of impotence. The preferred term confines the description to erectile function without implying absent desire, inability to experience orgasm, or infertility. (pubmed.ncbi.nlm.nih.gov)

Penile anatomy and erection physiology

The penis contains three longitudinal bodies of erectile tissue: two dorsolateral corpora cavernosa, which provide most of its rigidity, and a ventral corpus spongiosum, which surrounds the urethra and expands distally to form the glans. The corpora cavernosa contain interconnected, endothelial-lined blood spaces, or sinusoids, separated by trabeculae containing smooth muscle and connective tissue. Each is enclosed by the tunica albuginea, a tough fibrous sheath that limits expansion and participates in trapping blood during erection. The spongiosum has a thinner tunical covering and remains at lower pressure than the cavernosa during erection, allowing the urethral channel to remain relatively uncompressed. (pmc.ncbi.nlm.nih.gov)

Arterial blood usually reaches the penis through branches of the internal pudendal arteries. The cavernosal, or deep penile, arteries run within the corpora cavernosa and give rise to helicine arteries that deliver blood into the sinusoidal spaces. Dorsal penile arteries supply distal tissues, including the glans, while bulbar and urethral branches supply the corpus spongiosum. Venous blood leaves the erectile spaces through small subtunical veins and emissary veins that cross the tunica albuginea, joining drainage pathways that include the deep dorsal vein and internal pudendal veins. Anatomical variation and connections between arterial branches mean that this arrangement is not identical in every individual. (pmc.ncbi.nlm.nih.gov)

Erection coordinates sensory input, central processing, and autonomic output. Genital touch is conveyed principally through the dorsal penile nerve, a branch of the pudendal nerve, to sacral spinal pathways; visual, auditory, and imaginative stimuli act through the central nervous system. Parasympathetic outflow arises chiefly from spinal segments S2–S4, whereas sympathetic pathways arise predominantly from T11–L2. These autonomic fibers converge in the pelvic plexus and reach erectile tissue through the cavernous nerves. Parasympathetic-associated signaling favors smooth-muscle relaxation, while sympathetic noradrenergic activity helps maintain resting contraction. Somatic motor fibers in the pudendal nerve activate the ischiocavernosus and bulbospongiosus muscles, contributing to the rigid phase of erection. Reflexogenic erections follow genital stimulation, whereas psychogenic erections involve descending signals from the brain; these are interacting pathways rather than separate mechanical processes. (pmc.ncbi.nlm.nih.gov)

In the flaccid state, contracted arterial and trabecular smooth muscle restricts blood entry and leaves venous drainage open. During erection, relaxation dilates the resistance vessels and permits the sinusoids to expand. Expansion presses the subtunical venous plexuses against the tunica albuginea and compresses emissary outflow channels: this corporal veno-occlusive mechanism retains blood without requiring a venous valve to close. Intracavernosal pressure approaches systemic arterial pressure during full erection; contractions of the ischiocavernosus muscles can raise it to several hundred millimeters of mercury during the rigid phase. The corpus spongiosum and glans undergo less complete venous occlusion and therefore do not ordinarily attain the same pressure as the cavernosa. (pmc.ncbi.nlm.nih.gov)

The principal molecular relaxation pathway begins with nitric oxide (NO), produced by neuronal and endothelial nitric oxide synthases. NO diffuses into adjacent smooth-muscle cells and activates the enzyme soluble guanylyl cyclase, which converts guanosine triphosphate into cyclic guanosine monophosphate (cGMP). This intracellular messenger activates protein kinase G, reducing intracellular calcium availability and promoting relaxation. In a 1993 human tissue study, Arthur L. Burnett and colleagues localized nitric oxide synthase to the pelvic plexus, cavernous nerves, and nerve endings within erectile tissue, providing anatomical evidence for this signaling mechanism. Detumescence—the return to flaccidity—occurs as NO signaling declines, phosphodiesterase type 5 (PDE5) hydrolyzes cGMP to GMP, and sympathetic activity restores smooth-muscle contraction. Arterial inflow decreases, venous channels reopen, and retained blood drains from the cavernosa. (pmc.ncbi.nlm.nih.gov)

Clinical presentation and classification

Erectile dysfunction can present as difficulty initiating an erection, insufficient rigidity despite some penile enlargement, or loss of rigidity before sexual activity is completed. These manifestations need not occur together: an erection may develop readily but subside too soon, or persist without becoming sufficiently firm. Symptoms can be intermittent, with adequate erections on some occasions, or consistent, including an inability to obtain an erection at any time. Thus, the presence of occasional successful erections does not exclude erectile dysfunction, and the clinical presentation is not limited to complete absence of erections. (niddk.nih.gov)

Classification by onset distinguishes lifelong from acquired dysfunction. Lifelong dysfunction has been present since the individual first became sexually active, without a preceding period of satisfactory erectile function. Acquired dysfunction develops after such a period. Onset and subsequent course are separate characteristics: acquired symptoms may appear abruptly or develop gradually, while the principal difficulty may concern initiation, maintenance, or both. These descriptions identify the history of the problem rather than its mechanism; “lifelong” does not itself establish a congenital abnormality, and “acquired” does not specify a vascular or psychological cause. (pmc.ncbi.nlm.nih.gov)

Classification by context distinguishes generalized dysfunction, occurring across sexual circumstances, from situational dysfunction, restricted to particular circumstances, partners, or activities. One situational presentation is difficulty during partnered sexual activity despite adequate erections during masturbation. Another is difficulty with a particular partner but not with others. The American Urological Association’s 2018 guideline identifies these contextual differences, together with morning, nocturnal, and masturbatory erections, as relevant features of the presentation. Preserved morning or nocturnal erections suggest—but do not confirm—a psychological component; they are not sufficient by themselves to exclude an organic contribution. (manifold.counseling.org)

Etiological classification traditionally separates organic, psychogenic, and mixed dysfunction. Organic dysfunction involves physical contributors, commonly grouped as vascular, neurological, hormonal, structural, or medication-related. For example, atherosclerosis may restrict arterial inflow, whereas injury to the nervous system may interrupt erectile signaling. Psychogenic dysfunction describes erectile impairment associated with psychological or interpersonal factors, including performance-related distress, stress, and difficulties with sexual arousal or intimacy. It can be situational or generalized; a context-dependent presentation is therefore not the only possible psychogenic pattern. These categories concern contributing mechanisms, whereas lifelong/acquired and generalized/situational describe onset and distribution. (uroweb.org)

Mixed dysfunction denotes an organic contribution together with psychological factors that also influence erectile function. The International Continence Society’s 2022 terminology report gives anxiety and depression as examples of such accompanying factors. Psychological distress may worsen an existing physical impairment, so identifying an organic disorder does not remove the possibility of a psychological contribution. The European Association of Urology cautions that most cases involve mixed etiologies and notes the alternative terms “primarily organic” and “primarily psychogenic,” which identify the predominant contribution without treating the categories as mutually exclusive. In this usage, “primarily” refers to causal predominance, not to lifelong onset. (ics.org)

Epidemiology and population measurement

The Massachusetts Male Aging Study (MMAS) was a community-based, randomly sampled survey of noninstitutionalized men aged 40–70 in cities and towns near Boston, conducted in 1987–1989. Interviewers collected health and demographic information in participants’ homes, while erectile function was assessed through a self-administered sexual-activity questionnaire. Henry A. Feldman and colleagues reported the principal prevalence findings in 1994: 52% were classified as having minimal, moderate, or complete “impotence,” the terminology used in the original paper. This combined prevalence represented several degrees of erectile impairment, not a 52% prevalence of complete inability to achieve an erection. Complete impotence increased from approximately 5% at age 40 to 15% at age 70. These estimates describe the study’s population, period, and classification system rather than all adult men. (sciencedirect.com)

The Cologne Male Survey, published by M. Braun and colleagues in 2000, used a different instrument, the validated Cologne Erectile Dysfunction Questionnaire, in a population sample of 8,000 men aged 30–80. It obtained 4,489 evaluable postal replies, a response rate of 56.1%, and reported an overall ED prevalence of 19.2%. Age-specific estimates were 2.3% at ages 30–39, 9.5% at 40–49, 15.7% at 50–59, 34.4% at 60–69, and 53.4% at 70–80. Although both Cologne and MMAS showed a pronounced age gradient, their overall percentages are not directly interchangeable because their age ranges and measurement instruments differed. Cologne also distinguished erectile impairment from its operational measure of treatment need: 6.9% of respondents had both ED and dissatisfaction with their sex life. That narrower outcome measured something different from erectile function alone. (pubmed.ncbi.nlm.nih.gov)

Incidence measures new cases among men initially without the condition, rather than the proportion affected at a survey assessment. A longitudinal MMAS analysis published in 2000 followed 847 men without ED at baseline who had complete follow-up information, over an average of 8.8 years. The crude incidence was 25.9 cases per 1,000 person-years, with a 95% confidence interval of 22.5–29.9. Rates increased across baseline age groups: 12.4 per 1,000 person-years at ages 40–49, 29.8 at 50–59, and 46.4 at 60–69. In the Dutch Krimpen Study, reported in 2005, incidence depended strongly on the endpoint: rates were 99 per 1,000 person-years for reduced rigidity or worse, 33 for severely reduced rigidity or absent erections, and 28 for a definition incorporating both impairment and reported bother. Thus, even longitudinal estimates require the case definition to be specified. (pubmed.ncbi.nlm.nih.gov)

Questionnaire choice can produce substantial differences within the same population. In the 2004 ENIGMA study, B. J. de Boer and colleagues received 2,117 completed questionnaires after mailing surveys to 5,721 adult men registered with 12 Dutch general practices. Participants answered several erectile-function instruments. The International Index of Erectile Function produced the highest overall and age-specific prevalence estimates, whereas the Cologne questionnaire produced the lowest; the reported difference was 16.8 percentage points. Agreement between these two classifications was only moderate, with a kappa coefficient of 0.52. Differences in wording, scoring, and classification thresholds therefore can change who is counted as a case without any change in the surveyed population’s underlying health. (pubmed.ncbi.nlm.nih.gov)

Recruitment and disclosure also affect population measurement. The Cologne investigators explicitly identified social and cultural variation in the expression of sexual difficulties, while their response rates differed by age group, ranging from 49.2% to 68.4%. Nonresponse can distort an estimate if participation is related to erectile symptoms or willingness to discuss sexuality. Clinic samples have a different denominator from community surveys: they describe people attending or seeking care, not everyone living in a defined population. The longitudinal Krimpen research consequently examined community-reported symptoms separately from general-practice consultation and medication use. These distinctions prevent consultation rates, treatment use, and questionnaire-defined impairment from being treated as equivalent measures of disease frequency. (pubmed.ncbi.nlm.nih.gov)

Vascular, metabolic, and systemic causes

Vascular erectile dysfunction can result from inadequate arterial inflow, defective relaxation of erectile tissue, or failure to retain blood within the corpora cavernosa. Atherosclerosis can narrow the pelvic and penile arteries, limiting the increase in blood flow required for rigidity. Endothelial dysfunction is a functional impairment of the blood-vessel lining: reduced availability of nitric oxide weakens the signals that relax arterial and cavernosal smooth muscle, even without a major fixed arterial obstruction. These processes can coexist with impaired corporal veno-occlusion. Normally, expansion of the cavernous spaces compresses the draining veins against the tunica albuginea; inadequate smooth-muscle relaxation or reduced tissue compliance prevents effective compression. Loss of smooth muscle and increased collagen can therefore allow blood to escape before sufficient pressure is maintained. The expression “venous leak” describes this failure of blood retention, rather than necessarily identifying a single abnormal vein. (ncbi.nlm.nih.gov)

Diabetes mellitus can impair several components of this system simultaneously. Prolonged hyperglycemia damages blood vessels and nerves, combining reduced perfusion with impaired signaling to erectile tissue. Cavernosal relaxation in response to nitric oxide is also impaired in diabetes, potentially involving the accumulation of glycation products. Associated hypertension, abnormal blood lipids, and obesity can add further vascular impairment. In a 2017 meta-analysis, Youssef Kouidrat and colleagues combined 145 studies involving 88,577 men with diabetes. The pooled erectile-dysfunction prevalence was 59.1%, or 52.5% after adjustment for publication bias. Eight studies with nondiabetic comparison groups yielded an odds ratio of 3.62, with a 95% confidence interval of 2.53–5.16. These estimates describe heterogeneous study populations, not an inevitable outcome for an individual with diabetes. (niddk.nih.gov)

Hypertension, dyslipidemia, and obesity are associated with vascular erectile dysfunction and frequently occur together. High blood pressure and abnormal lipid levels can accompany arterial disease and impaired endothelial function; elevated cholesterol contributes to atherosclerotic disease. Obesity overlaps with these vascular risks and with diabetes, making it difficult to isolate the contribution of body weight alone. The European Association of Urology consequently lists hypertension, hyperlipidemia, diabetes, obesity, and metabolic syndrome among relevant causes or risk factors rather than treating them as mutually exclusive diagnoses. Medication-related erectile effects represent an additional, distinct mechanism and cannot automatically be attributed to the underlying hypertension. (ncbi.nlm.nih.gov)

Chronic kidney disease likewise has a multifactorial relationship with erectile dysfunction. Vascular disease and endothelial impairment may coexist with diabetic nerve damage, autonomic dysfunction, hormonal disturbances, anemia, and medication effects. Thus, erectile difficulty in a man receiving dialysis is not explained simply by reduced kidney filtration or by dialysis itself. A 2024 cross-sectional study of men undergoing hemodialysis in an urban Brazilian Amazon setting reported erectile dysfunction in 66.3% of participants, with associations including older age and diabetes. Such dialysis-based findings concern a population with advanced kidney disease and substantial comorbidity; they do not establish the same prevalence or causal mechanism across all stages of kidney disease. (ncbi.nlm.nih.gov)

Smoking, physical inactivity, and excessive alcohol consumption are recognized associated factors, but the evidence does not justify assigning every exposed individual the same causal pathway. In a 2000 prospective report from the Massachusetts Male Aging Study, Howard Feldman and colleagues analyzed 513 men initially free of erectile dysfunction and without diabetes, heart disease, or related medication exposure. Baseline cigarette smoking predicted approximately twice the likelihood of subsequent moderate or complete erectile dysfunction. A separate report that year by Carol Derby and colleagues found the highest risk among persistently sedentary men and lower risk among men who remained active or became active. Excessive alcohol use can contribute through central nervous-system suppression, alcoholic neuropathy, and vascular impairment. Nevertheless, observational associations remain susceptible to confounding by age, illness, and other behaviors; neither these cohort findings nor a plausible biological mechanism alone proves the magnitude of a direct causal effect. (pubmed.ncbi.nlm.nih.gov)

Neurological, hormonal, and structural causes

Spinal cord injury can interrupt descending signals from the brain while leaving some local erectile reflexes intact. Reflexogenic erections, elicited by genital touch, depend on sensory input and a sacral reflex circuit involving spinal segments S2–S4; psychogenic erections, elicited by thoughts or other centrally processed stimuli, depend on descending pathways and preserved thoracolumbar circuitry, particularly T11–L2. Consequently, an injury above the sacral segments may preserve reflex erections while impairing mentally induced erections, whereas damage to the sacral cord or its nerve roots can abolish the reflex response. The pattern depends on the neurological level and completeness of the lesion, rather than simply on whether paralysis is present. Preserved erections may still lack sufficient rigidity or duration for intercourse. The Consortium for Spinal Cord Medicine’s 2010 clinical practice guideline therefore distinguishes preserved erectile responses from fully functional erections. (pmc.ncbi.nlm.nih.gov)

Other neurological disorders can affect different components of this signaling system. Multiple sclerosis may disrupt conduction in the central nervous system, while Parkinson’s disease and stroke can affect central control of sexual responses. Peripheral neuropathy, including that associated with diabetes mellitus, can impair genital sensation or autonomic nerve transmission. Neurological disease does not necessarily produce a purely neurogenic disorder: the European Association of Urology distinguishes primary sexual dysfunction from direct neurological damage, secondary effects of physical disability, and tertiary psychosocial effects. Fatigue, restricted mobility, emotional distress, and concurrent vascular disease may therefore coexist with impaired neural signaling. (ncbi.nlm.nih.gov)

Testosterone deficiency can contribute to erectile difficulty, particularly when accompanied by reduced sexual desire and fewer spontaneous or morning erections. Primary hypogonadism originates in impaired testicular function—for example, after bilateral testicular injury or orchitis—whereas secondary hypogonadism results from inadequate hypothalamic or pituitary stimulation, including that associated with pituitary tumors. Low testosterone also occurs alongside obesity and chronic systemic illness, so its presence does not establish that it is the sole cause of erectile dysfunction. Erectile symptoms and reduced desire are related but distinct: androgen deficiency may affect both, while vascular or neurological damage can remain important determinants of rigidity. Clinical hypogonadism requires compatible symptoms together with consistently low testosterone concentrations, rather than an isolated laboratory result. (uroweb.org)

Other endocrine disturbances include excess prolactin and thyroid dysfunction. Hyperprolactinemia can reduce the gonadotropin signals that normally stimulate the testes, lowering testosterone production; affected men may develop reduced desire and erectile dysfunction. A prolactin-secreting pituitary adenoma is one specific cause. Hypothyroidism can itself elevate prolactin, while both hypothyroidism and hyperthyroidism are recognized among endocrine conditions associated with erectile difficulty. These mechanisms can overlap rather than represent mutually exclusive diagnoses. (endocrine.org)

Structural abnormalities can interfere with sexual activity independently of, or together with, inadequate rigidity. In Peyronie’s disease, fibrous plaque develops in the tunica albuginea, the envelope surrounding the erectile bodies. Restricted expansion can produce curvature, shortening, narrowing, or an unstable indentation during erection; pain and erectile dysfunction may accompany the deformity. Mechanical inability to penetrate despite a rigid erection is not itself the same as erectile dysfunction. Congenital curvature, which reflects disproportionate development of the tunica albuginea rather than acquired plaque formation, illustrates this distinction: severe curvature can make intercourse difficult without necessarily preventing erection. (niddk.nih.gov)

Pelvic and perineal trauma can combine neurological, vascular, and structural injury. A straddle injury—such as falling onto a bicycle crossbar—can damage perineal nerves or vessels, disrupting genital sensation or penile blood supply. Pelvic fractures may injure erectile pathways alongside the posterior urethra. The European Association of Urology’s trauma guideline reports erectile dysfunction in approximately 34% of patients with pelvic-fracture urethral injury, attributable to the underlying injury rather than urethroplasty; this estimate concerns that specific injury group, not all pelvic fractures. Penile fracture, a rupture of the tunica albuginea, can also leave fibrosis, deformity, and erectile impairment. (niddk.nih.gov)

Medication effects and cancer-treatment consequences

Medication-associated erectile difficulties are not uniform effects of entire drug classes. The European Association of Urology lists thiazide diuretics and some beta-blockers, antidepressants, antipsychotics, and antiandrogens among implicated medicines. Interpretation is complicated by the fact that conditions being treated, notably hypertension and depression, can themselves impair erectile function. Exposure to a medicine therefore does not, by itself, establish causation. Differences between individual agents are clinically relevant: the 2007 randomized, double-blind MR NOED study found less adverse effect on erectile function with nebivolol than with metoprolol, despite similar blood-pressure reduction. Nebivolol has nitric-oxide-mediated vasodilator properties, illustrating why findings for one beta-blocker cannot automatically be extended to all others. (uroweb.org)

Psychotropic medicines may affect several sexual domains, which must be distinguished from erectile dysfunction specifically. Selective serotonin reuptake inhibitors such as sertraline can produce adverse sexual effects involving desire, erection, ejaculation, or orgasm. In a 2000 randomized trial led by psychiatrist R. Taylor Segraves, 248 patients received sustained-release bupropion or sertraline for 16 weeks; sexual dysfunction was more frequent with sertraline, although both treatments had similar antidepressant efficacy. These sexual-dysfunction outcomes are not equivalent to an erectile-dysfunction rate. Some antipsychotics also interfere with endocrine signaling: risperidone’s dopamine $D_2$-receptor blockade elevates prolactin, which can suppress hypothalamic gonadotropin-releasing hormone and reduce pituitary gonadotropin secretion. Its prescribing information identifies impotence among reported consequences of prolactin-elevating drugs. (pubmed.ncbi.nlm.nih.gov)

Antiandrogens and other forms of androgen-deprivation therapy used for prostate cancer act through a different pathway. Androgen-receptor antagonists block androgen action, whereas gonadotropin-releasing hormone agonists or antagonists reduce testicular testosterone production. These treatments can impair erections while also reducing sexual desire; the two effects may coexist but are not interchangeable. Recovery after treatment ends depends partly on testosterone recovery. The National Cancer Institute notes that testosterone may not return fully to previous levels, particularly in older men and after prolonged androgen deprivation, allowing sexual adverse effects to persist. Concurrent hormone therapy also complicates attribution of erectile difficulties following prostate irradiation. (cancer.gov)

Pelvic cancer surgery, including radical cystectomy and rectal operations, can damage autonomic nerves involved in erection. Radical prostatectomy is particularly consequential because the cavernous nerves run close to the prostate within neurovascular bundles. Their removal or operative injury can interrupt erectile signaling, producing an abrupt postoperative loss of function. Nerve-sparing surgery preserves these structures when tumor characteristics permit, but does not guarantee normal erections afterward. Younger age, better preoperative erectile function, the quality of nerve preservation, and surgical experience are associated with better outcomes. Recovery may occur gradually over the first two postoperative years rather than immediately; preserved nerves and recovered erectile function are therefore distinct outcomes. (cancer.gov)

Prostate radiotherapy, whether external-beam treatment or brachytherapy, can injure erectile nerves and blood vessels. Subsequent scarring and arterial narrowing can impair penile blood supply. Compared with surgery, deterioration commonly develops more gradually: radiation-associated difficulties may first become apparent six months to two years after treatment and may progress over subsequent years. Risk varies with radiation dose and the volume treated, as well as age and pre-existing vascular damage associated with diabetes mellitus, cardiovascular disease, or smoking. These mechanisms help explain why preserved erections shortly after irradiation do not establish long-term preservation. (cancer.gov)

Treatment-specific trajectories were demonstrated in Jenny Donovan and colleagues’ 2016 ProtecT report, involving 1,643 men randomly assigned to active monitoring, prostatectomy, or radiotherapy with neoadjuvant androgen deprivation. At baseline, 67% reported erections firm enough for intercourse. At six years, the corresponding proportions were 30%, 17%, and 27%, respectively. Surgery produced the greatest early deterioration, followed by some recovery, whereas radiotherapy produced an early decline with partial recovery and later deterioration. These figures describe the trial’s patients and treatment protocols, not universal probabilities for every contemporary technique; they also measure reported functional erections rather than proving recovery of spontaneous, treatment-unassisted function. (pmc.ncbi.nlm.nih.gov)

Psychological, relational, and quality-of-life dimensions

Performance anxiety can create a self-reinforcing cycle: an episode of erectile difficulty prompts anticipation of another failure, increased monitoring of penile rigidity, and distraction from erotic sensations. Subsequent difficulties may strengthen negative expectations and avoidance of sexual activity. Stress arising from work, illness, or a life crisis can also interfere with sexual engagement. These processes can accompany vascular, neurological, or hormonal impairment; psychological distress does not establish that erectile dysfunction (ED) is exclusively psychogenic. European Association of Urology guidance therefore includes sexual expectations, self-esteem, mood, and cognitive distraction in assessment of both predominantly organic and predominantly psychogenic presentations. (uroweb.org)

Depression and erectile difficulties have a reciprocal association. Depressive symptoms may precede ED, while persistent erectile difficulties can contribute to loss of confidence and emotional distress. In a 2018 meta-analysis, Qian Liu and colleagues identified 49 eligible publications. Studies examining depression as the exposure produced a pooled odds ratio for ED of 1.39 (95% confidence interval, 1.35–1.42); studies examining ED as the exposure produced a pooled odds ratio for depression of 2.92 (2.37–3.60). The first estimate showed substantial between-study heterogeneity, with $I^2=93.6\%$. These findings describe an association rather than proving a single direction of causation, and the odds ratios are not absolute probabilities that either condition will develop. (pubmed.ncbi.nlm.nih.gov)

Relationship context influences both the experience of symptoms and their consequences. Emotional disconnection, dissatisfaction, and expectations about sexual performance are associated with erectile difficulties, but such associations do not identify either partner as responsible. Intimacy and communication are relevant alongside rigidity, particularly when sexual encounters become tests of performance rather than mutually satisfying experiences. Effects on quality of life can extend to the partner’s sexual satisfaction and well-being. In the 2005 FEMALES study, William A. Fisher and colleagues surveyed 293 female partners of men with ED. Participants retrospectively reported less frequent sexual activity and lower levels of desire, arousal, orgasm, and relationship-related sexual satisfaction after their partner developed ED. Because this was a questionnaire study involving female partners, its findings neither establish causality nor represent every relationship configuration. (uroweb.org)

Psychosexual assessment examines the meaning attached to erectile difficulties, anticipatory anxiety, sexual beliefs, life stressors, relationship communication, and coexisting mental health symptoms. It complements rather than replaces medical evaluation. Psychological treatment may include education about sexual response, sexual-skills training, and cognitive-behavioral therapy (CBT). CBT addresses maladaptive predictions and behavior—for example, interpreting an unsuccessful encounter as evidence of inevitable future failure—and works to reduce performance-focused anxiety. Couple-based approaches can address communication and shared expectations, with partner involvement where appropriate. Individual, group, couple, and online formats have been studied; European Association of Urology guidance supports combining psychological and medical treatment when indicated. (uroweb.org)

Evidence for combined treatment includes a 2007 randomized pilot trial by Linda L. Banner and Rodney U. Anderson involving 53 men with psychogenic ED and their female partners. After four weeks, 48% receiving sildenafil plus cognitive-behavioral sex therapy met the study’s erectile-function success criterion, compared with 29% receiving sildenafil alone; corresponding satisfaction success rates were 65.5% and 37.5%. A 2021 systematic review of 13 articles involving 597 men likewise found benefits from combining psychological interventions with phosphodiesterase-5 inhibitors, including improvements in erectile function and sexual satisfaction. The review could not establish which psychological approach was superior and called for larger studies; its included populations were adults aged 19–55 with psychogenic ED, limiting generalization to other presentations. (pubmed.ncbi.nlm.nih.gov)

Clinical history, examination, and severity assessment

The clinical history establishes when erectile difficulty began, how long it has persisted, its frequency, and whether the principal problem is attaining rigidity, maintaining it, or both. Assessment records the hardness and duration of erections during partnered activity and masturbation, spontaneous morning or nighttime erections, and variation between partners or sexual situations. Preserved morning erections suggest, but do not establish, a psychological component; they do not exclude coexisting physical disease. Previous treatment use and response, the degree of distress, and the patient’s expectations also help characterize the presenting problem. (auau.auanet.org)

Sexual history distinguishes erectile difficulty from reduced desire, impaired arousal, ejaculatory disturbances, and orgasmic problems. Medical history covers chronic illnesses, pelvic operations or injury, and prescribed medicines, over-the-counter products, vitamins, and supplements. Relevant conditions include diabetes mellitus, hypertension, and neurological disease. Mental-health symptoms and relationship circumstances are assessed alongside physical factors rather than treated as competing explanations. Information from a partner, when available and appropriate, can clarify the timing and context of symptoms. (niddk.nih.gov)

The focused examination covers genital, vascular, neurological, and endocrine findings. Genital inspection and palpation can identify penile lesions, deformity, or plaques associated with Peyronie’s disease; a palpable plaque alone does not establish the functional significance of a deformity. Vascular assessment includes blood pressure and pulse, while neurological assessment looks for relevant abnormalities of sensation or nervous-system function. Endocrine findings may suggest testosterone deficiency. Body mass index or waist circumference documents adiposity and associated metabolic risk. These findings can identify previously unrecognized comorbidities even when they do not establish a single cause of erectile difficulty. (auau.auanet.org)

Standardized questionnaires quantify symptoms and provide repeatable measures of treatment response. Raymond C. Rosen and colleagues published the 15-item International Index of Erectile Function (IIEF) in 1997, following linguistic validation in ten languages. Its five domains assess erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. The five-item version, IIEF-5, also commonly called the Sexual Health Inventory for Men (SHIM), concentrates on erectile function and intercourse satisfaction. Its 1999 validation included 1,152 men—1,036 with erectile dysfunction and 116 controls. A cutoff of 21 distinguished erectile dysfunction from no dysfunction with sensitivity of 0.98 and specificity of 0.88 in that study; scores of 22–25 indicated no dysfunction and 5–7 severe dysfunction. These are measurement categories, not explanations of the underlying cause. (pubmed.ncbi.nlm.nih.gov)

The single-item Erection Hardness Score (EHS) measures rigidity more narrowly: grade 1 denotes enlargement without hardness; grade 2, hardness insufficient for penetration; grade 3, sufficient hardness for penetration without complete rigidity; and grade 4, complete hardness and rigidity. John P. Mulhall and colleagues reported its psychometric validation in 2007 using data from 307 participants in a multinational sildenafil trial. The score demonstrated test–retest reliability and responsiveness to treatment, but measures hardness rather than the broader dimensions covered by the IIEF. (pubmed.ncbi.nlm.nih.gov)

Selected blood tests investigate metabolic and hormonal contributors. European Association of Urology guidance includes fasting glucose or glycated haemoglobin (HbA1c), together with a lipid profile, if these have not been assessed within the preceding 12 months. These tests can uncover diabetes or lipid abnormalities relevant to vascular function. Hormonal assessment includes fasting, early-morning total testosterone; calculated free or bioavailable testosterone may help clarify some results. Luteinizing hormone and prolactin are selected according to associated signs and symptoms, while thyroid testing may investigate suspected thyroid disease. Laboratory abnormalities are interpreted with the history and examination: their presence does not, by itself, prove that they account for the erectile symptoms. (uroweb.org)

Specialized diagnostic investigations

Specialized investigations address particular questions about erectile mechanisms rather than forming a routine test battery for every patient. The American Urological Association’s 2018 guideline identifies them as potentially necessary when their findings can guide treatment; most cases are evaluated initially through history, examination, and selected laboratory tests. Examples warranting additional investigation include suspected vascular impairment, an inadequate response to oral treatment, and pelvic or perineal trauma in a young man being considered for arterial reconstruction. These tests assess different aspects of erectile function and do not provide interchangeable evidence about its cause. (auau.auanet.org)

An intracavernosal injection test examines the erectile response to a vasoactive medicine injected into the corpora cavernosa. In an office setting, the examiner observes the fullness, rigidity, and duration of the resulting erection. This tests the response to pharmacological stimulation, rather than an erection arising in the usual sexual context. A rigid response demonstrates erectile capacity under those conditions, but the injection test alone supplies limited information about vascular status: it does not adequately distinguish reduced arterial inflow from impaired retention of blood within the erectile tissues. When that distinction is clinically important, injection testing can be combined with duplex imaging. (niddk.nih.gov)

Dynamic penile duplex ultrasonography evaluates penile blood flow after pharmacological stimulation. Doppler measurements quantify peak systolic velocity, which reflects arterial inflow, and end-diastolic velocity, which helps assess corporal veno-occlusion. The European Association of Urology lists peak systolic velocity above $30\ \mathrm{cm/s}$, end-diastolic velocity below $3\ \mathrm{cm/s}$, and a resistance index above $0.8$ as commonly accepted normal findings. These are interpretive thresholds, not definitive diagnoses in isolation. Anxiety or an insufficient pharmacological response can produce falsely abnormal findings, and protocols and haemodynamic criteria are not completely standardized. A normal, adequately performed examination generally makes further vascular investigation unnecessary. (uroweb.org)

Nocturnal penile tumescence and rigidity monitoring records sleep-associated erections, either at home or in a sleep laboratory. Devices such as RigiScan measure changes in penile circumference, rigidity, and the duration and number of erectile episodes. Assessment over at least two nights reduces reliance on a single recording; an episode with at least 60% rigidity at the penile tip lasting ten minutes or longer is one guideline criterion for a functional erectile mechanism. Preserved nocturnal erections can support a psychogenic contribution, but do not establish that all symptoms are psychological. Conversely, abnormal recordings are not conclusive evidence of organic disease: sleep quality, age, depression, and the unfamiliar testing context can affect results. Nocturnal erections also do not reproduce the sensory and interpersonal conditions of sexual activity. (niddk.nih.gov)

Invasive vascular investigations are reserved for narrowly defined questions. Selective internal pudendal arteriography maps arterial anatomy and obstructive lesions, chiefly when penile revascularization is being considered after trauma. Cavernosometry measures intracavernosal pressure responses during fluid infusion; cavernosography uses contrast imaging to depict venous drainage. These investigations have historically been used to examine suspected corporal veno-occlusive dysfunction, but are now infrequently performed. Their interpretation remains imperfect: a standard-operating-procedure review by Sidney Glina and Hussein Ghanem, published in 2013, emphasized uncertainty about cavernosometry’s positive predictive value and the frequency of falsely abnormal results in men with normal erectile function. Their invasive nature and limited relevance to many treatment decisions restrict their use outside selected specialist assessments. (pmc.ncbi.nlm.nih.gov)

Cardiovascular significance

Vascular erectile dysfunction (ED) is a clinical marker of cardiovascular disease, reflecting processes that can affect both penile and systemic circulation. Shared mechanisms include endothelial dysfunction, vascular inflammation, and atherosclerosis; shared risk factors include smoking, hypertension, diabetes mellitus, and obesity. Dysfunction of the vascular endothelium impairs the vasodilation needed to increase penile blood flow, while atherosclerotic narrowing limits arterial supply. Consequently, erectile difficulty can be a manifestation of vascular disease rather than an isolated genital disorder. The American Urological Association’s 2018 guideline explicitly identifies ED as a marker of underlying cardiovascular disease that may warrant further evaluation. This association does not mean that every case of ED has a vascular origin. (auanet.org)

Longitudinal studies quantify the association with subsequent events. A 2013 meta-analysis by Charalambos Vlachopoulos and colleagues included 14 studies with 92,757 participants and a mean follow-up of 6.1 years. Compared with men without ED, those with ED had pooled relative risks of 1.44 for total cardiovascular events, 1.62 for myocardial infarction, and 1.39 for cerebrovascular events; the corresponding 95% confidence intervals were 1.27–1.63, 1.34–1.96, and 1.23–1.57. Relative associations were stronger at younger ages and in intermediate-risk populations. These figures describe relative differences between study groups, not an individual’s absolute probability of an event. (pubmed.ncbi.nlm.nih.gov)

Evidence also supports prediction after adjustment for conventional risk factors. In a 2018 analysis of the Multi-Ethnic Study of Atherosclerosis, S. M. Iftekhar Uddin and colleagues followed 1,757 men without previous cardiovascular events for approximately 3.8 years. ED remained associated with major cardiovascular events after adjustment for demographic characteristics, smoking, diabetes, blood pressure, cholesterol measures, medication use, and depression: the adjusted hazard ratio was 1.9, with a 95% confidence interval of 1.1–3.4. Such observational prediction does not establish causation. ED and cardiovascular events may be different manifestations of an underlying disease process, and statistical adjustment cannot exclude all residual confounding. Nor do these findings demonstrate that restoring erections, by itself, prevents myocardial infarction or stroke. (ahajournals.org)

The Princeton consensus frameworks distinguish long-term cardiovascular risk assessment from the immediate cardiac demands of sexual activity. The first conference took place in 1999; Princeton IV convened in March 2023, with guidelines published in 2024. For men with predominantly vascular ED but no known cardiovascular disease, Princeton IV incorporates estimation of 10-year atherosclerotic cardiovascular disease risk, primarily for ages 40–79. Assessment includes age, smoking, blood pressure, cholesterol, and diabetes. The framework proposes coronary artery calcium measurement by computed tomography for borderline-to-intermediate estimated risk, approximately 5%–20%, to refine assessment of subclinical coronary artery disease. Particular attention is given to men aged 40–60, whose risk may be underestimated by strongly age-dependent calculators. These are consensus-based clinical pathways, not evidence that ED alone diagnoses coronary obstruction. (academic.oup.com)

For men with established cardiovascular disease, treatment planning additionally considers clinical stability and exercise tolerance. Princeton-based pathways classify patients as low, indeterminate, or high risk for cardiac events during sexual activity. Controlled hypertension and successful coronary revascularization can fall within the low-risk category, whereas unstable angina, uncontrolled hypertension, and severe symptomatic heart failure belong to higher-risk categories in which stabilization precedes sexual activity and ED treatment. Indeterminate cases may undergo exercise stress testing; achieving approximately 5–6 metabolic equivalents without ischemia supports low-risk classification. Medication review is also essential: phosphodiesterase type 5 inhibitors are contraindicated with organic nitrates because their combined vasodilatory effects can cause an unpredictable fall in blood pressure. This interaction is distinct from the cardiovascular significance of ED itself. (academic.oup.com)

Management principles and underlying conditions

Management is individualized according to the cause and severity of erectile difficulty, associated illnesses, previous treatment responses, and the patient’s sexual goals and preferences. The American Urological Association’s 2018 guideline makes shared decision-making central to treatment selection: all medically appropriate options can be discussed without requiring every patient to follow a fixed sequence from tablets to invasive procedures. Informed consent involves comparing expected efficacy, adverse effects, invasiveness, reversibility, practical burdens, and cost—not merely whether an intervention can produce an erection. Preferences concerning spontaneity, preparation, and partner involvement can influence selection; choosing not to pursue erection-specific treatment is also an option. (auanet.org)

Treatment of contributing conditions can proceed before or alongside symptom-directed therapy. Relevant conditions include diabetes mellitus, hypertension, lipid abnormalities, and endocrine disorders. Their management addresses broader health risks as well as potentially reversible contributors to erectile difficulty; correction of a risk factor does not necessarily eliminate the need for erection-specific treatment. Medication review distinguishes the effects of the underlying illness from possible adverse effects of its treatment. When a medicine is suspected of contributing, clinical management may include supervised dose adjustment or substitution, while preserving treatment of the original condition. Psychological or emotional contributors may be addressed concurrently through counseling, rather than being treated as alternatives to physical causes. (uroweb.org)

Lifestyle interventions have measurable but variable effects. A 2023 systematic review of 11 randomized controlled trials, involving 1,147 men, found that aerobic exercise improved the erectile-function domain of the International Index of Erectile Function by an average of 2.8 points compared with controls, with a 95% confidence interval of 1.7–3.9 points on a standardized 6–30 scale. Study populations, exercise interventions, and concurrent use of erectile medicines differed, and statistical heterogeneity was moderate. These findings support an average improvement in measured function, not a guarantee that exercise restores normal erections in every individual. Proposed mechanisms include improved vascular endothelial function and changes in blood pressure, body weight, and glucose regulation. (academic.oup.com)

Weight-related evidence includes Katherine Esposito and colleagues’ 2004 trial of 110 men aged 35–55 with obesity and erectile dysfunction, but without diabetes, hypertension, or hyperlipidemia. After two years, 17 of 55 participants receiving an intensive dietary and physical-activity intervention reached the study’s erectile-function threshold of at least 22 points, compared with 3 of 55 receiving general information. Mean body mass index fell from 36.9 to 31.2 in the intervention group and from 36.4 to 35.7 in controls. Because diet, weight loss, and physical activity changed together, the trial did not isolate the contribution of each component; its selected population also limits generalization. Smoking cessation and reduction of excessive alcohol consumption are included in risk-factor management, but their erectile benefits cannot be assumed to match those of this intervention. (pubmed.ncbi.nlm.nih.gov)

Treatment effectiveness in practice also depends on continued use. A systematic review published in 2021 reported discontinuation rates ranging from 4.4% to 76% for oral phosphodiesterase type 5 inhibitors across included studies. Common barriers included perceived ineffectiveness, adverse effects, relationship factors, and treatment costs; these widely varying estimates are not a single expected dropout rate. Follow-up therefore includes reassessing response, tolerability, and whether treatment still fits the patient’s goals. An erection achieved with medication or a device represents treatment-assisted function, not necessarily recovery of unassisted function. For example, the AUA guideline found that early use of oral erection medicines after prostate-cancer treatment could assist erections during treatment, without demonstrating improved subsequent unassisted erectile recovery. (openaccess.city.ac.uk)

Oral medicines and hormonal treatment

Oral phosphodiesterase type 5 inhibitors (PDE5 inhibitors) amplify the normal erectile response rather than initiating it independently. Sexual stimulation promotes nitric oxide release in penile tissue, increasing cyclic guanosine monophosphate (cGMP), which relaxes cavernosal smooth muscle and facilitates blood inflow. PDE5 is the enzyme that breaks down cGMP; inhibiting it prolongs this signal. Sildenafil, tadalafil, vardenafil, and avanafil therefore require sexual stimulation and are not medicines that directly increase sexual desire. Their action supports an erection during an effective treatment window, not a continuous erection throughout that period. (accessdata.fda.gov)

The four drugs differ principally in their time course and treatment format. Sildenafil is used on demand, generally begins acting within 30–60 minutes, and has a plasma elimination half-life of approximately four hours; its prescribing information documents erectile effects up to four hours, with a diminished response compared with two hours. Vardenafil is also used on demand, usually begins acting within about 30 minutes, and has a half-life of approximately four to five hours. Thus, both are relatively short-acting options. Tadalafil has a much longer half-life, approximately 17.5 hours, and demonstrated efficacy up to 36 hours after administration. It has both on-demand and once-daily treatment formats; daily treatment separates medication timing from individual sexual encounters. Avanafil is an on-demand option with an onset as early as 15–30 minutes and a terminal half-life of approximately five hours. Half-life describes drug elimination, however, and is not an exact measure of the duration of erectile benefit. (accessdata.fda.gov)

Response varies with the severity and cause of dysfunction, residual erectile signaling, treatment exposure, and sexual context. Inadequate stimulation, unsuitable timing, or delayed absorption can produce apparent treatment failure. High-fat meals can delay absorption of sildenafil, vardenafil, and avanafil, whereas tadalafil absorption is not materially affected by food. The European Association of Urology notes that clarification of timing and stimulation requirements can restore responses in some apparent nonresponders. Trial percentages are also outcome-dependent: reporting “improved erections” is not equivalent to reporting successful intercourse on every attempt. For example, avanafil trials reported mean successful-intercourse attempt rates of 47–59% across treatment groups, compared with 28% with placebo; these figures describe attempts, not the proportion of men permanently recovering unassisted function. (uroweb.org)

Common adverse effects include headache, flushing, indigestion, nasal congestion, and dizziness. Sildenafil can produce transient visual disturbances, including altered color perception; back pain and muscle pain are particularly associated with tadalafil. Product labeling also records uncommon prolonged erections and reports of sudden visual or hearing loss, although temporal association alone does not establish drug causation for every reported event. An erection lasting longer than four hours is classified in labeling as requiring emergency assessment because prolonged erection can damage erectile tissue. (accessdata.fda.gov)

Concurrent use with organic nitrates or nitrites is contraindicated because both treatments enhance nitric oxide–cGMP signaling and can cause a dangerous fall in blood pressure. This includes nitrate medicines such as nitroglycerin and recreational nitrites commonly called “poppers.” The guanylate cyclase stimulator riociguat is likewise contraindicated. Alpha-blockers and other blood-pressure-lowering medicines can add to hypotensive effects, while strong CYP3A4 inhibitors can substantially increase drug exposure. Vardenafil has an additional drug-specific limitation involving QT-interval prolongation, including restrictions in congenital long-QT conditions and with certain antiarrhythmic medicines. (accessdata.fda.gov)

Testosterone treatment has a narrower role: correcting established male hypogonadism, rather than treating erectile dysfunction indiscriminately. The Endocrine Society’s 2018 guideline requires compatible symptoms or signs together with unequivocally and consistently low testosterone concentrations, confirmed by repeat morning fasting measurements; a single low result is insufficient. Replacement may improve sexual desire and erectile function in deficient men, and some deficient patients who respond poorly to PDE5 inhibitors improve after testosterone treatment. Available formats include transdermal, intramuscular, and oral preparations. Treatment entails monitoring clinical response, testosterone concentrations, hematocrit, and relevant prostate parameters. Exogenous testosterone suppresses sperm production, making fertility intentions an important treatment consideration. (endocrine.org)

Local medicines and vacuum devices

Intracavernosal injection therapy delivers vasoactive medicines directly into the corpora cavernosa, rather than relying on absorption through the gastrointestinal tract. Alprostadil, a synthetic form of prostaglandin E1, increases intracellular cyclic adenosine monophosphate (cAMP), relaxing cavernosal smooth muscle and dilating penile arteries. The resulting expansion of erectile tissue compresses venous outflow and retains blood within the penis. This local action can produce an erection without the sexual stimulation required by oral phosphodiesterase type 5 inhibitors. Licensed injectable formulations include Caverject and Edex; treatment initiation involves supervised assessment and training rather than unsupervised experimentation. (accessdata.fda.gov)

Combination injections employ drugs with complementary actions. Bimix contains papaverine and phentolamine; Trimix adds alprostadil. These preparations are not standardized across formulations, and their non-prostaglandin ingredients are not FDA-approved specifically for erectile dysfunction. European Association of Urology guidelines summarize efficacy exceeding 70% for intracavernosal alprostadil and reaching approximately 92% for Trimix in published studies; these are not guaranteed individual response rates. Lower alprostadil exposure in combinations may reduce penile pain, while papaverine-containing preparations carry an appreciable risk of fibrosis. Injections can also cause local bleeding or bruising, prolonged unwanted erections, and priapism. Fibrotic plaques and penile deformity have been reported during treatment. Practical burdens include needle aversion, preparation, and interruption of sexual activity; published injection-program discontinuation rates of 41–68% show that pharmacological efficacy does not necessarily translate into sustained use. (uroweb.org)

Intraurethral alprostadil uses a small medicated pellet, exemplified by the Medicated Urethral System for Erection (MUSE). The drug is absorbed across the urethral mucosa and transferred to surrounding erectile tissues, avoiding direct injection into the corpora cavernosa. Its effectiveness is generally lower than that of intracavernosal delivery. In a 1997 randomized controlled trial reported by Harin Padma-Nathan and colleagues, 1,511 men underwent initial clinical testing, and 65.9% achieved an erection sufficient for intercourse. Among initial responders who subsequently reported home-treatment outcomes, 64.9% receiving alprostadil had intercourse successfully at least once over three months, compared with 18.6% receiving placebo. These home-treatment percentages therefore describe a selected responder population, not all men starting treatment. Penile or urethral pain, burning, minor urethral bleeding, and occasional dizziness or hypotension limit tolerability. (nejm.org)

A vacuum erection device produces rigidity mechanically. A cylinder surrounding the penis is connected to a manual or powered pump; negative pressure draws blood into the penis, while a constriction ring at the base reduces venous drainage after the vacuum is released. The approach is drug-free and does not depend on the same biochemical response as medicines. Reported rates of erections satisfactory for intercourse reach 90%, but satisfaction varies widely, from 27% to 94%, reflecting differences in populations, devices, and acceptability. Devices with vacuum-pressure limiters reduce the risk of excessive suction. (niddk.nih.gov)

Vacuum devices can cause petechiae, bruising, discomfort, numbness, and a cold or purplish appearance; the ring may impede ejaculation without necessarily preventing orgasm. Excessive or prolonged constriction can injure penile tissue, distinguishing ring-related ischemia from drug-induced prolonged erections. Device handling and the altered appearance or sensation of the erection are additional practical limitations. Bleeding disorders and anticoagulant treatment are relevant safety considerations because suction and constriction can increase bruising or bleeding. Unlike injections, vacuum devices do not introduce a drug into erectile tissue, but they exchange needle-related burdens for mechanical handling and constriction-related effects. (niddk.nih.gov)

Prostheses and reconstructive surgery

A penile prosthesis provides mechanical rigidity rather than restoring the vascular or neurological processes that normally produce an erection. Implantation is an option when other treatments are ineffective or unsuitable, or when an informed patient prefers an implant. Because the operation alters the erectile tissues and is essentially irreversible, informed consent includes expectations about appearance, postoperative discomfort, device use, complications, and possible further operations. The American Urological Association’s 2018 guideline also excludes implantation in the presence of systemic, operative-site skin, or urinary tract infection. (uroweb.org)

Inflatable prostheses contain paired cylinders placed within the corpora cavernosa. A three-piece system connects these cylinders to a pump in the scrotum and a separate fluid reservoir in the abdomen or pelvis. Pumping transfers fluid into the cylinders, producing rigidity; a release mechanism allows fluid to return to the reservoir, reducing rigidity. A two-piece system incorporates fluid storage into the implanted components without a separate abdominal reservoir. Malleable prostheses instead use paired bendable rods: the penis remains firm but can be positioned outward for intercourse or toward the body for concealment. Their simpler operation can suit limited manual dexterity, although persistent firmness makes concealment less natural than with a deflated inflatable device. (baus.org.uk)

Implants support shaft rigidity but do not directly treat reduced sexual desire or restore damaged sensory nerves. Penile sensation and the capacity for orgasm are generally preserved, rather than enhanced by the device; underlying disease or previous treatment may still affect these functions. The glans does not necessarily become more rigid, and an implant does not correct pre-existing ejaculatory impairment. Perceived shortening and differences from a natural erection are important postoperative concerns. In the studies summarized by the European Association of Urology, reported satisfaction ranged from 92–100% among recipients and 91–95% among partners following appropriate counseling. These figures describe selected study populations, not guaranteed outcomes or proof that one implant design is superior. (baus.org.uk)

Infection and mechanical failure are the principal reasons for implant removal or revision. The European guideline reports infection rates around 2–3% for primary implantation in low-risk patients at high-volume centers, and approximately 1–2% with antibiotic-impregnated or hydrophilic-coated devices. Infection generally requires device removal and antibiotics; selected cases undergo immediate replacement after surgical washout. Mechanical failure may require component replacement or a new implant. A pooled analysis cited by the guideline estimated implant survival at 87.2% after five years and 76.8% after ten years, distinguishing long-term device survival from immediate surgical success. Other complications include erosion into surrounding tissues and reservoir-related injury. (uroweb.org)

Penile arterial reconstruction differs from implantation because it attempts to restore arterial inflow. Its role is narrowly confined to selected young men with focal pelvic or penile arterial obstruction, particularly after pelvic or perineal injury, without generalized vascular disease or impaired corporal veno-occlusion. It is not a general treatment for diffuse atherosclerotic erectile dysfunction. The AUA’s 2018 guideline classifies reconstruction as a conditional option supported by low-quality evidence and emphasizes that long-term success is difficult to predict even in apparently suitable candidates. Penile venous surgery, which attempts to reduce blood outflow by ligating veins, is not recommended by either the American or European guideline because durable benefit has not been demonstrated for most patients. (auanet.org)

Clinical course and post-treatment rehabilitation

Erectile function can remain impaired, fluctuate, improve, or deteriorate rather than follow a uniformly progressive course. A 2007 analysis by Thomas G. Travison and colleagues of the Massachusetts Male Aging Study examined 401 men aged 40–70 with erectile difficulties: 35% exhibited remission at follow-up, while 33% of the 323 men with minimal or moderate dysfunction progressed to a more severe category. Among 78 men initially classified as having complete dysfunction, 58% remained in that category. Age and body mass index were associated with both progression and remission; smoking and self-assessed health were associated with progression. These observational findings document changing symptom severity, not a universal probability of recovery or proof that modifying any single factor causes remission. (pubmed.ncbi.nlm.nih.gov)

After radical prostatectomy for prostate cancer, recovery depends particularly on preoperative erectile function, age, and preservation of the cavernous nerves. Even nerve-sparing surgery can produce neuropraxia—a temporary interruption of nerve function following injury—so anatomical preservation does not imply immediately preserved erections. Additional vascular injury and secondary changes in denervated erectile tissue can contribute to persistent dysfunction. The American Urological Association guideline describes spontaneous recovery as commonly occurring over 12–24 months, with further improvement possible up to 36 months; improvement nevertheless need not mean return to the preoperative baseline. Complete loss of the cavernous nerve supply has a different prognosis from temporary conduction impairment. By contrast, erectile impairment after radiotherapy may develop gradually, including onset 24–36 months after treatment, and can subsequently worsen. (auanet.org)

Post-prostatectomy penile rehabilitation aims to facilitate resumption of sexual activity while attempting to improve eventual erectile recovery. Programs may include phosphodiesterase type 5 inhibitors, vacuum erection devices, or intracavernosal medicines, separately or in combination. Two outcomes must be distinguished: treatment-assisted function, in which an erection occurs with a medicine or device, and spontaneous recovery, in which adequate erections occur without those aids. A higher erectile-function questionnaire score during treatment can therefore demonstrate symptomatic benefit without demonstrating restoration of unassisted function. The European Association of Urology guideline recognizes postoperative treatment benefits but finds insufficient evidence to identify an optimal rehabilitation regimen or establish that rehabilitation increases spontaneous recovery after nerve-sparing prostatectomy. (uroweb.org)

The REACTT randomized controlled trial, published in 2014, illustrates this distinction. It allocated 423 men with normal preoperative erectile function following bilateral nerve-sparing prostatectomy to daily tadalafil, on-demand tadalafil, or placebo for nine months. After a six-week drug-free washout, an International Index of Erectile Function erectile-function domain score of at least 22 was achieved by 20.9%, 16.9%, and 19.1%, respectively; neither tadalafil group differed significantly from placebo. Daily tadalafil improved drug-assisted function during treatment, but that advantage did not establish improved unassisted recovery after withdrawal. Moreover, reaching the trial’s questionnaire threshold was not necessarily equivalent to regaining each participant’s preoperative level of function. (pubmed.ncbi.nlm.nih.gov)

Evidence remains sensitive to treatment schedules, recovery definitions, and follow-up duration. A 2018 Cochrane review covering eight randomized trials and 1,699 participants found that scheduled PDE5-inhibitor treatment might provide little or no advantage over on-demand use for self-reported potency or erectile function, with predominantly very-low- or low-certainty evidence. A later network meta-analysis of 22 studies involving 2,711 patients reported favorable recovery estimates for certain regular sildenafil schedules and pelvic-floor training, although certainty differed between interventions. These differing findings do not establish a single protocol that reliably restores baseline function. In particular, outcomes recorded while treatment continues and outcomes assessed after withdrawal answer different questions, while follow-up shorter than the potential nerve-recovery period leaves long-term spontaneous recovery incompletely characterized. (pmc.ncbi.nlm.nih.gov)

Historical development of erectile medicine

The transition from “impotence” to erectile medicine involved both a narrower clinical definition and an expanding account of sexual function. The 1992 National Institutes of Health (NIH) statement criticized the older term for its imprecision and pejorative implications: failure to achieve an erection did not necessarily imply loss of desire, orgasm, or ejaculation. Its replacement, “erectile dysfunction,” identified a particular functional difficulty rather than a general incapacity for sexual activity. This distinction also clarified the object of clinical research, allowing investigations of penile physiology and treatment outcomes to address erection specifically while retaining psychological, behavioral, and relational dimensions. (scribd.com)

Experimental pharmacology helped establish that erectile difficulty could be investigated through local physiological mechanisms. In October 1983, British physiologist Giles S. Brindley published a study of intracavernosal phenoxybenzamine, an alpha-adrenergic blocking drug. His report described full erections in six of eleven men with erectile impotence following injection. Local alpha blockade provided a way to investigate the contribution of sympathetic signaling and cavernosal smooth-muscle relaxation, rather than treating erectile performance solely as an expression of psychological state. The study was small and reported markedly prolonged responses, but it demonstrated a pharmacologically accessible mechanism and helped establish the basis for injection treatment. (pubmed.ncbi.nlm.nih.gov)

The NIH Consensus Development Conference on Impotence, held on December 7–9, 1992, consolidated a biological and psychosocial approach. Its remit included prevalence, clinical and social effects, risk factors, diagnostic assessment, treatment efficacy and risks, public and professional awareness, and research priorities. The panel recommended replacing “impotence” with “erectile dysfunction” and emphasized that, although erectile difficulties became more likely with increasing age, they were not an inevitable consequence of aging. It also concluded that assessment and treatment should respond to individual needs, including the patient’s and partner’s expectations and willingness to continue treatment. Thus, physiological investigation and psychosocial assessment were presented as complementary components of care. (pubmed.ncbi.nlm.nih.gov)

The conference’s public-health conclusions extended beyond terminology. It identified embarrassment and reluctance among both patients and clinicians to discuss sexual matters as contributors to underdiagnosis, and called for education about sexuality, sexual dysfunction, and available treatments. It also recognized erectile dysfunction as an important public-health problem requiring greater support for basic and applied research. These conclusions distinguished an often-treatable clinical condition from an assumed consequence of aging or a difficulty left outside ordinary medical discussion. (pubmed.ncbi.nlm.nih.gov)

On March 27, 1998, the United States Food and Drug Administration approved Pfizer’s sildenafil citrate, marketed as Viagra, marking a major development in oral pharmacological treatment. Sildenafil enhanced the erectile response to sexual stimulation by inhibiting cyclic GMP breakdown in the corpus cavernosum. A report published on May 14, 1998, by Irwin Goldstein, Tom F. Lue, Harin Padma-Nathan, and colleagues described two double-blind randomized controlled trials, enrolling 532 and 329 men respectively, with organic, psychogenic, or mixed causes. During the final four weeks of the second trial, 69% of intercourse attempts were successful with sildenafil, compared with 22% with placebo; these figures measured attempts, not the proportion of men cured. Oral administration offered a less invasive alternative to injections and implantation. In April 1999, a multidisciplinary Process of Care Consensus Panel published a model explicitly intended to support assessment and treatment in primary care, reflecting the expansion of erectile medicine beyond specialist practice. (accessdata.fda.gov)

Access to care, product regulation, and research

Embarrassment, uncertainty about treatment, and reluctance to discuss sexual symptoms can leave erectile dysfunction unreported and clinically unrecognized. These are barriers to diagnosis and care, not evidence of a particular physiological cause. A Taiwanese clinic study published in 2009 illustrates the communication gap: among 844 questionnaire respondents with type 2 diabetes, 708 had erectile dysfunction, but only 14.2% of all respondents had consulted a Western-medicine physician about it. Embarrassment and misinformation about treatment were leading reasons for not seeking such care. Among respondents with erectile dysfunction, 56.6% wanted to discuss it with their doctors; of these, 90.4% preferred the doctor to initiate the conversation. Because this was a selected diabetic outpatient population, these percentages do not represent all men with erectile dysfunction. (pubmed.ncbi.nlm.nih.gov)

Products marketed as “natural” sexual enhancers may contain undeclared prescription medicines rather than solely the ingredients shown on their labels. On October 23, 2015, the United States Food and Drug Administration (FDA) reported that laboratory testing of Wild Sexx Capsules had detected both sildenafil and tadalafil. Undeclared exposure is a patient-safety problem because these medicines can interact with nitrate drugs, including nitroglycerin, and cause dangerously low blood pressure. The FDA also emphasized that it cannot test every potentially adulterated product; absence from a warning list therefore does not establish safety. Dietary supplements do not undergo FDA premarket approval for safety and effectiveness, although manufacturers remain responsible for applicable safety, labeling, and manufacturing requirements. (fda.gov)

Low-intensity extracorporeal shockwave treatment applies acoustic pulses to penile tissue and has been investigated particularly in vasculogenic erectile dysfunction. Reported improvements are generally modest, and studies differ in generators, energy settings, treatment schedules, and patient selection. Focused shockwaves and radial pressure-wave treatments cannot simply be treated as equivalent: a randomized radial-wave trial found no advantage over placebo on erectile-function and hardness scores. Guideline interpretations differ. The European Association of Urology describes a mild benefit in selected vasculogenic cases, whereas the American Urological Association’s 2018 guideline classifies low-intensity shockwave treatment as investigational. Neither position establishes reliable, lasting restoration of unassisted erections across all causes of erectile dysfunction. (uroweb.org)

Platelet-rich plasma injections are intended to expose tissue to concentrated platelet-derived growth factors, but proposed regenerative mechanisms do not themselves demonstrate clinical benefit. Trials have produced conflicting results, and preparation methods and injection protocols vary. Stem-cell approaches likewise remain under investigation: the European guideline describes 18 phase I–II trials involving 373 patients, with only four small placebo-controlled studies and conflicting efficacy findings. These data do not establish routine effectiveness or comprehensive long-term safety. (uroweb.org) Gene therapy has also reached early human testing. In December 2006, Arnold Melman and colleagues reported a phase I study in 11 men receiving a plasmid encoding a subunit of the Maxi-K potassium channel, intended to enhance cavernosal smooth-muscle relaxation. No serious adverse events were reported during 24 weeks of observation, but the uncontrolled safety study could not establish efficacy. (pubmed.ncbi.nlm.nih.gov)

Evaluation of these interventions depends on blinded, sham- or placebo-controlled randomized controlled trials, rather than improvement from baseline alone. Relevant outcomes include validated International Index of Erectile Function scores, clinically meaningful changes, adverse events, and durability during follow-up. Concurrent use of established medicines also matters: an improvement while taking a phosphodiesterase inhibitor is not necessarily recovery of unassisted function. Regulatory status answers a separate question. FDA establishment registration or device listing does not signify approval; 510(k) device clearance generally concerns substantial equivalence to a legally marketed predicate. Authorization must be interpreted in relation to the specified intended use, rather than as blanket evidence for every advertised erectile-dysfunction claim. (auanet.org)

References

1. ERECTILE DYSFUNCTION: AUA GUIDELINEauanet.org
2. Erectile dysfunction (impotence)nhs.uk
3. MANAGEMENT OF ERECTILE DYSFUNCTIONuroweb.org
4. Disorders of Ejaculation - EAU Guidelines on Sexual and Reproductive Healthuroweb.org
5. Infertility and Fertilitynichd.nih.gov
6. Impotencepubmed.ncbi.nlm.nih.gov
7. Investigation of erectile dysfunctionpmc.ncbi.nlm.nih.gov
8. Physiology of Penile Erection and Pathophysiology of Erectile Dysfunctionpmc.ncbi.nlm.nih.gov
9. Anatomical Considerations for Endovascular Penile Interventionspmc.ncbi.nlm.nih.gov
10. Normal Penile, Scrotal, and Perineal Anatomy with Reconstructive Considerationspmc.ncbi.nlm.nih.gov
11. Clinical Neuroanatomy and Neurotransmitter-Mediated Regulation of Penile Erectionpmc.ncbi.nlm.nih.gov
12. Neuroanatomy of penile erection: its relevance to iatrogenic impotencepubmed.ncbi.nlm.nih.gov
13. Endothelial Nitric Oxide Synthase Keeps Erection Regulatory Function Balance in the Penispmc.ncbi.nlm.nih.gov
14. Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penispubmed.ncbi.nlm.nih.gov
15. Physiological significance of nitrergic transmission in human penile erectionpubmed.ncbi.nlm.nih.gov
16. Symptoms & Causes of Erectile Dysfunction - NIDDKniddk.nih.gov
17. ERECTILE DYSFUNCTION: AUA GUIDELINEauanet.org
18. Erectile dysfunction: Proposed definition and staging for early diagnosispmc.ncbi.nlm.nih.gov
19. Erectile Dysfunction — Counseling Nexusmanifold.counseling.org
20. ICS Standards 2023ics.org
21. MANAGEMENT OF ERECTILE DYSFUNCTIONuroweb.org
22. Erectile dysfunction (ED) - Mixedics.org
23. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'pubmed.ncbi.nlm.nih.gov
24. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging studypubmed.ncbi.nlm.nih.gov
25. Incidence rates of erectile dysfunction in the Dutch general population. Effects of definition, clinical relevance and duration of follow-up in the Krimpen Studypubmed.ncbi.nlm.nih.gov
26. Impact of various questionnaires on the prevalence of erectile dysfunction. The ENIGMA-study.pubmed.ncbi.nlm.nih.gov
27. Erectile dysfunction in the community: trends over time in incidence, prevalence, GP consultation and medication use--the Krimpen study: trends in EDpubmed.ncbi.nlm.nih.gov
28. Classification and Common Causes of Erectile Dysfunctionncbi.nlm.nih.gov
29. Medical and Surgical Therapy of Erectile Dysfunctionncbi.nlm.nih.gov
30. Chronic kidney disease and erectile dysfunctionpmc.ncbi.nlm.nih.gov
31. Diabetes, Sexual, & Bladder Problemsniddk.nih.gov
32. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studiesgala.gre.ac.uk
33. Erectile dysfunction among men with chronic kidney disease undergoing hemodialysis in a Brazilian Amazon urban setting: an epidemiological studybjnephrology.org
34. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging studypubmed.ncbi.nlm.nih.gov
35. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk?pubmed.ncbi.nlm.nih.gov
36. Sexuality and Reproductive Health in Adults with Spinal Cord Injury: A Clinical Practice Guideline for Health-Care Professionalspmc.ncbi.nlm.nih.gov
37. Diagnosis and Treatment of Erectile Dysfunctionncbi.nlm.nih.gov
38. The Guideline - EAU Guidelines on Neuro-urologyuroweb.org
39. Male Hypogonadism - EAU Guidelines on Sexual and Reproductive Healthuroweb.org
40. Hyperprolactinemiaendocrine.org
41. Penile Curvature (Peyronie's Disease)niddk.nih.gov
42. Penile Curvature - EAU Guidelines on Sexual and Reproductive Healthuroweb.org
43. Perineal Injury in Malesniddk.nih.gov
44. EAU Guidelines on Urological Trauma - Urogenital Trauma Guidelinesuroweb.org
45. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive menpubmed.ncbi.nlm.nih.gov
46. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatmentpubmed.ncbi.nlm.nih.gov
47. DailyMed - RISPERIDONE tabletdailymed.nlm.nih.gov
48. Hormone Therapy for Prostate Cancer Fact Sheet - NCIcancer.gov
49. Sexual Health Issues in Men and Cancer Treatment - Side Effects - NCIcancer.gov
50. How Cancer Can Affect Erectionscancer.org
51. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancerpmc.ncbi.nlm.nih.gov
52. Erectile Dysfunction: AUA Guidelineauau.auanet.org
53. Erectile Dysfunction and Depression: A Systematic Review and Meta-Analysispubmed.ncbi.nlm.nih.gov
54. Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) studypubmed.ncbi.nlm.nih.gov
55. Counselling for erectile dysfunction - Patient Informationpatients.uroweb.org
56. Integrated sildenafil and cognitive-behavior sex therapy for psychogenic erectile dysfunction: a pilot studypubmed.ncbi.nlm.nih.gov
57. The effectiveness of psychological interventions alone, or in combination with phosphodiesterase-5 inhibitors, for the treatment of erectile dysfunction: A systematic reviewpubmed.ncbi.nlm.nih.gov
58. Diagnosis of Erectile Dysfunction - NIDDKniddk.nih.gov
59. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunctionpubmed.ncbi.nlm.nih.gov
60. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunctionpubmed.ncbi.nlm.nih.gov
61. Validation of the erection hardness scorepubmed.ncbi.nlm.nih.gov
62. The erection hardness score and its relationship to successful sexual intercoursepubmed.ncbi.nlm.nih.gov
63. Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunctionpmc.ncbi.nlm.nih.gov
64. Penile revascularization—contemporary updatepmc.ncbi.nlm.nih.gov
65. Evaluation of erectile dysfunction by dynamic infusion cavernosometry and cavernosography (DICC). Multi-institutional study.pubmed.ncbi.nlm.nih.gov
66. SOP: corpus cavernosum assessment (cavernosography/cavernosometry).pubmed.ncbi.nlm.nih.gov
67. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studiespubmed.ncbi.nlm.nih.gov
68. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health - PubMedpubmed.ncbi.nlm.nih.gov
69. Treatment for Erectile Dysfunction — NIDDKniddk.nih.gov
70. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trialpubmed.ncbi.nlm.nih.gov
71. Men’s beliefs about treatment for erectile dysfunction – What influences treatment use? A systematic Reviewopenaccess.city.ac.uk
72. VIAGRA (sildenafil citrate) prescribing informationaccessdata.fda.gov
73. DailyMed — Vardenafil hydrochloride tablet, film coateddailymed.nlm.nih.gov
74. DailyMed — CIALIS tadalafil tablet, film coateddailymed.nlm.nih.gov
75. DailyMed — STENDRA avanafil tabletdailymed.nlm.nih.gov
76. Testosterone Therapy for Hypogonadism Guideline Resources — Endocrine Societyendocrine.org
77. CAVERJECT (alprostadil) for injection, for intracavernosal useaccessdata.fda.gov
78. Treatment for Erectile Dysfunction - NIDDKniddk.nih.gov
79. Erectile Dysfunction: AUA Guidelineauanet.org
80. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Grouppubmed.ncbi.nlm.nih.gov
81. Penile prostheses (implants) — British Association of Urological Surgeonsbaus.org.uk
82. Treating erectile dysfunction — Mayo Clinic Health Systemmayoclinichealthsystem.org
83. The natural progression and remission of erectile dysfunction: results from the Massachusetts Male Aging Studypubmed.ncbi.nlm.nih.gov
84. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT)pubmed.ncbi.nlm.nih.gov
85. Effects of Tadalafil Once-Daily or On-Demand vs Placebo on Return to Baseline Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy—Results from a Randomized Controlled Trial (REACTT)pubmed.ncbi.nlm.nih.gov
86. Penile rehabilitation for postprostatectomy erectile dysfunctionpmc.ncbi.nlm.nih.gov
87. Penile Rehabilitation Strategy after Nerve Sparing Radical Prostatectomy: A Systematic Review and Network Meta-Analysis of Randomized Trialspubmed.ncbi.nlm.nih.gov
88. NIH Consensus on Erectile Dysfunctionscribd.com
89. Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotencepubmed.ncbi.nlm.nih.gov
90. Effect of local alpha-adrenergic blockade on human penile erectionpubmed.ncbi.nlm.nih.gov
91. Consensus development conference statement. National Institutes of Health. Impotence. December 7-9, 1992pubmed.ncbi.nlm.nih.gov
92. Viagra Cover Sheetaccessdata.fda.gov
93. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.pubmed.ncbi.nlm.nih.gov
94. The process of care model for evaluation and treatment of erectile dysfunction. The Process of Care Consensus Panel.pubmed.ncbi.nlm.nih.gov
95. Patterns and their correlates of seeking treatment for erectile dysfunction in type 2 diabetic patients.pubmed.ncbi.nlm.nih.gov
96. Public Notification: Wild Sexx Capsules contain hidden drug ingredientsfda.gov
97. Is It Really 'FDA Approved'?fda.gov
98. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial.pubmed.ncbi.nlm.nih.gov
99. Ion channel gene therapy for smooth muscle disorders: relaxing smooth muscles to treat erectile dysfunction.pubmed.ncbi.nlm.nih.gov
100. General/Specific Intended Use - Guidance for Industryfda.gov